Logistic Properties of the Americas Third Quarter 2025 Supplemental Information LPA Parque Logístico Calle 80 – Bogota, Colombia LPA Parque Logístico San José Verbena –San Jose, Costa Rica LPA Parque Logístico Calle 80 – Bogota, Colombia Disclaimer This presentation (the "Presentation") is provided for informational purposes only and has been prepared to provide interested parties with certain information about Logistic Properties of the Americas and its subsidiaries (collectively, "LPA") and for no other p ...

3Q25 Performance - Total revenue increased by 8.8% to $1.577 billion in 3Q25[14] - Adjusted EBITDA grew by 46.3% to $143 million in 3Q25[14] - Adjusted EBITDA margin expanded by 240 bps to 9.1% in 3Q25[14] - Operating cash flow increased by 72.1% to $154 million in 3Q25[14] Year-to-Date (YTD) Performance - Total revenue increased by 8.2% to $4.719 billion YTD[14] - Adjusted EBITDA increased by 30.1% to $411 million YTD[14] - Adjusted EBITDA margin expanded by 150 bps to 8.7% YTD[14] - Operating cash flow increased by 26.4% to $247 million YTD[14] Volume and Revenue Drivers - Admissions increased by 5.8% in 3Q25 and 6.7% YTD[12] - Adjusted admissions increased by 2.9% in 3Q25 and 2.4% YTD[12] - Net patient service revenue per adjusted admission grew by 5.8% to $17,252 in 3Q25[14] Full-Year 2025 Guidance - Total revenue guidance reaffirmed at $6.2 billion to $6.45 billion[25] - Adjusted EBITDA guidance revised to $530 million to $555 million[25] - Adjusted admissions growth expected to be between 2.0% and 3.0%[25]

Core Insights - EuroDry Ltd. reported its financial results for the third quarter and the first nine months of 2025, highlighting a decrease in net revenues and an increase in adjusted EBITDA compared to the same periods in 2024 [1][2][3]. Third Quarter 2025 Highlights - Total net revenues for the third quarter were $14.4 million, a 2.2% decrease from $14.7 million in Q3 2024, primarily due to a reduced average number of vessels operating [12]. - The net loss attributable to controlling shareholders was $0.7 million, or a loss of $0.24 per share, compared to a net loss of $4.2 million, or $1.53 per share, in Q3 2024 [21][23]. - Adjusted EBITDA for the quarter was $4.1 million, significantly up from $0.5 million in the same quarter of the previous year [22]. - An average of 12.0 vessels were owned and operated during the quarter, earning an average time charter equivalent rate of $13,232 per day [12]. Nine Months 2025 Highlights - Total net revenues for the first nine months were $34.9 million, representing a 25.1% decrease from $46.6 million in the same period of 2024, attributed to fewer vessels operated and lower charter rates [25]. - The net loss attributable to controlling shareholders for the nine months was $7.4 million, or $2.71 per share, compared to a loss of $6.4 million, or $2.34 per share, in the first nine months of 2024 [35][36]. - Adjusted EBITDA for the nine-month period was $5.0 million, down from $7.6 million in the same period of 2024 [36]. Recent Developments and Financing Arrangements - The company signed an agreement to sell the M/V Eirini P. for approximately $8.5 million, with a gain of $0.7 million recorded upon delivery [5]. - EuroDry entered into a refinancing agreement with Eurobank S.A. for a total loan of up to $39.5 million to finance the construction of new vessels and refinance existing loans [5]. - A loan agreement was signed with Crediabank S.A. for up to $26.9 million to finance pre-delivery installments for another newbuilding [5]. Market Conditions and Future Outlook - The drybulk market has shown improvement, with average Ultramax spot earnings just below $15,000 per day during Q3 and exceeding $17,000 per day since early October [7]. - The company anticipates that the market improvement will be reflected in Q4 results, as many charters were finalized at lower rates prior to the market uptick [8]. - Steps taken to improve liquidity, including refinancing and vessel sales, are expected to increase liquidity by approximately $15 million by the end of 2025 [9].

Core Insights - SINTX Technologies, Inc. reported third quarter financial results and provided a business update, focusing on its commercialization plan for infection-resistant silicon nitride devices and polymer composites [1][2]. Business Highlights and Key Milestones - The company received FDA 510(k) clearance for the SINAPTIC Foot & Ankle Osteotomy Wedge System, marking a significant milestone for commercial entry into reconstructive foot and ankle surgery in the U.S. [5][7]. - Initial product revenue was recorded from the OsseoSculpt™ product, a companion biologic to the SINAPTIC wedge portfolio [7]. - SINTX executed a sublease of the Armor facility, projected to save approximately $950,000 in lease costs, aligning resources with medical device priorities [7]. - The company raised an additional $4.3 million through warrant inducement and common stock warrant exercises, strengthening its liquidity [7]. Financial Results - Cash and cash equivalents increased to $6.25 million as of September 30, 2025, compared to $3.60 million on December 31, 2024 [7]. - Total revenue for Q3 2025 was $0.208 million, a decrease from $0.799 million in Q3 2024, primarily due to reduced grant revenue [7]. - Operating expenses were approximately $3.4 million, a 51% decrease year-over-year [7]. - The operating loss was $3.4 million, down from $6.4 million in Q3 2024, while the net loss was $3.5 million, or $1.19 per fully diluted share, compared to a net loss of $6.2 million, or $6.96 per fully diluted share in Q3 2024 [7]. Future Priorities - SINTX plans to prepare the SINAPTIC wedge system for launch, expand clinical engagement in targeted surgical specialties, and leverage its material science into adjacent indications [5]. - The company is also evaluating options for partnering, licensing, and capital formation to enhance market access and shareholder value [5].

Accelerating profitable growth and building a new TAD tissue facility to start-up in 2028MISSISSAUGA, Ontario, Nov. 13, 2025 (GLOBE NEWSWIRE) -- KP Tissue Inc. (KPT) (TSX: KPT) reports the Q3 2025 financial and operational results of KPT and Kruger Products Inc. (Kruger Products or the Company). Kruger Products is Canada's leading manufacturer of quality tissue products for the Consumer market (Cashmere®, Purex®, SpongeTowels®, Scotties®, White Swan® and Bonterra®) and the Away-From-Home (AFH) market and co ...

Link Media Outdoor - Revenue increased by 2.5% YoY to $11.8 million in Q3 2025[9, 11] - Adjusted EBITDA reached a record high of approximately $4.8 million, a 5.6% increase YoY[9, 11] - Land costs accounted for 18.2% of revenue[9, 11] Boston Omaha Broadband - Total new fiber passings were approximately 4.2k, with approximately 1.7k new fiber subscribers YTD 2025[14] - Adjusted EBITDA was approximately $3.2 million, which excludes Fiber Fast Homes[9] - Fiber Fast Homes revenue increased by 68.4% YoY to $0.7 million in Q3 2025[17] - Fiber Fast Homes had approximately 0.4k new fiber passings and approximately 1.2k new fiber subscribers YTD 2025[17, 18] General Indemnity Group - Revenue increased by 4.7% YoY[9, 21] - The loss ratio was 25.3%, attributed to larger claim payments and increased reserves on outstanding contract bonds[9, 21] - Adjusted EBITDA was approximately negative $0.3 million[9] Investments and Cash - Sky Harbour investments had a GAAP value of $82.7 million and a market value of $126.9 million[24] - The company had unrestricted cash of $22.9 million and U S Treasury securities of $18.2 million as of September 30, 2025[26]

Core Insights - Pelthos Therapeutics Inc. reported strong commercial performance for ZELSUVMI, generating $7.1 million in net revenues during its first quarter of operations [1][5] - The company has successfully launched ZELSUVMI, the first FDA-approved at-home treatment for molluscum contagiosum, with 2,716 units prescribed by 1,169 unique prescribers in Q3 2025 [1][5] - The acquisition of XEPI adds a complementary product to Pelthos' portfolio, targeting the same pediatric market as ZELSUVMI, enhancing revenue potential [3][5] Financial Performance - For the three months ended September 30, 2025, Pelthos reported total revenue of $7.4 million, with net product revenues from ZELSUVMI at $7.1 million [10] - The company incurred a net loss of $16.2 million, translating to a loss of $5.30 per share [9][10] - Cash and cash equivalents as of September 30, 2025, stood at $14.2 million, reflecting a significant increase from $513,000 in December 2024 [7] Operational Highlights - The commercial launch of ZELSUVMI exceeded expectations, with strong market uptake and continued growth anticipated in Q4 2025 [3][5] - The company completed a merger to form Pelthos Therapeutics and raised $50.1 million in an equity private placement to support ZELSUVMI's launch [5] - An additional $18 million in private convertible notes financing was closed in November 2025 to facilitate the purchase and relaunch of XEPI and expedite ZELSUVMI's commercial rollout [5] Market Context - ZELSUVMI addresses a significant unmet need in treating molluscum contagiosum, primarily affecting children, while XEPI targets antibiotic-resistant skin infections, further solidifying Pelthos' position in the pediatric dermatology market [3][5] - The combined addressable markets for ZELSUVMI and XEPI present substantial revenue opportunities for Pelthos, leveraging existing commercial relationships and infrastructure [3][5]

Core Insights - Rubicon Organics Inc. reported strong financial results for Q3 2025, with net revenue of CAD 15.6 million, a 16% increase year-over-year, and Adjusted EBITDA of CAD 1.7 million, reflecting operational scale and cost control [3][8][9] Financial Performance - Q3 2025 net revenue reached CAD 15.6 million, up from CAD 13.5 million in Q3 2024, while year-to-date (YTD) revenue for 2025 was CAD 43.0 million, a 25% increase compared to the same period in 2024 [9][12] - Adjusted EBITDA for Q3 2025 was CAD 1.7 million, with YTD Adjusted EBITDA at CAD 3.8 million, marking the sixth consecutive quarter of positive Adjusted EBITDA [3][9][12] - Gross profit for Q3 2025 was CAD 8.0 million, with a gross profit margin of 33.7%, compared to 32.4% in Q3 2024 [12] Market Position and Growth Strategy - The company has a national market share of 6.2% in premium flower and pre-rolls, 13.2% in premium vapes, and 16.0% in premium edibles for Q3 2025 [9] - Rubicon's acquisition of the Cascadia Facility is expected to increase production capacity by over 40%, supporting future growth in both domestic and international markets [7][11] - The company has successfully shipped to three international markets in the fiscal year, indicating a strategic focus on global expansion [9] Operational Highlights - The company has begun investing in talent and foundational initiatives to support growth as it prepares to realize revenue from the Cascadia Facility in 2026 [2][3] - Cash flow from operations for Q3 2025 was CAD 0.5 million, with total current assets amounting to CAD 35.6 million as of September 30, 2025 [9][12] Future Outlook - For fiscal 2025, the company forecasts growth in both net revenue and Adjusted EBITDA, despite anticipated one-time costs related to the Cascadia Facility [11][20] - The company remains confident in its long-term value creation potential, driven by ongoing expansion and strategic initiatives [11][20]

Core Insights - Ravelin Properties REIT reported its highest quarterly gross rental revenue and net operating income since Q3 2024, indicating a return to stability in same-property net operating income for the first time since Q2 2024 [3][4] - The REIT signed 235,163 square feet of new leases and renewals in Q3 2025 at a weighted average net rental rate of $18.29 per square foot, which is 20.5% above prior rental rates for previously vacant spaces [4] - The current leasing pipeline exceeds 895,000 square feet, with over 100,000 square feet of rent reviews underway in Ireland, presenting opportunities to increase in-place rents [4] Financial Performance - For the three months ended September 30, 2025, rental revenue was $47.5 million, a decrease of 5.2% from $50.2 million in the same period of 2024 [6] - Net operating income (NOI) for Q3 2025 was $21.3 million, down 12.2% from $24.3 million in Q3 2024 [6] - The REIT reported a net loss of $17.4 million for Q3 2025, a significant improvement compared to a net loss of $182.1 million in Q3 2024 [6] Occupancy and Property Management - As of September 30, 2025, portfolio occupancy was 74.5%, down from 75.8% as of June 30, 2025, primarily due to a known vacancy at 280 Broadway in Winnipeg [4] - Management is considering redeveloping high-vacancy properties, including a potential conversion of 280 Broadway into a self-storage facility [4] Liquidity and Debt Metrics - The REIT's liquidity as of September 30, 2025, included unrestricted cash of $12.2 million, a decrease from $13.6 million at the end of 2024 [4] - The net debt to adjusted EBITDA ratio was reported at 14.5x, up from 12.9x at the end of 2024, indicating increased leverage [6][21] - Adjusted EBITDA for the trailing twelve months was $76.4 million, down from $89.4 million in the previous year [19][21] Future Outlook - The REIT is in discussions with senior lenders to extend forbearance agreements that expired on September 30, 2025, with no agreement reached as of the report date [5] - The acquisition of a 25% co-ownership interest in two GTA properties is expected to further reduce the net debt to adjusted EBITDA ratio in upcoming quarters [4]

VIQ Solutions Reports Adjusted EBITDA Up 72% and 115% for the Three and Nine Months Ended September 30, 2025; Scalable Operational Architecture Integrated Into Australian Operations Expected to Contribute Over $3 Million AnnuallyNovember 12, 2025 5:45 PM EST | Source: VIQ Solutions Inc.Revenue of $10.9 million and $31 million for the three and nine months ended September 30, 2025, with gross margins up 1.5% and 3.7%, respectively.Adjusted EBITDA of $1.4 million and $3.2 million for the three a ...